SCHEDULE: Armistice Capital Acquires 9.99% Stake in CalciMedica

Armistice Capital, LLC, through its Master Fund, has acquired a 9.99% stake in CalciMedica, Inc., reporting beneficial ownership of 3,411,361 shares.

Summary

• Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 3,411,361 shares of CalciMedica, Inc. common stock.
• This holding represents 9.99% of the class of securities.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd is the managing member of Armistice Capital, LLC.
• The filing indicates that Armistice Capital exercises voting and investment power over the securities held by the Master Fund.
• The Master Fund disclaims beneficial ownership due to the investment management agreement with Armistice Capital.
• The filing date for this event is June 30, 2026, with the report filed on August 14, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating a significant but not controlling stake acquisition by an investment manager, which could signal confidence in the company's future prospects.

Positives

• Acquisition of a significant stake (9.99%) by an investment manager can be interpreted as a positive signal of confidence in the company's value or future growth.
• The filing indicates a structured investment approach by Armistice Capital, LLC, suggesting a potentially engaged and informed shareholder.

Negatives

• The filing does not contain any negative financial results or operational challenges.
• The Master Fund disclaims beneficial ownership, which could imply a degree of separation or specific investment mandate.

Risks

• As a Schedule 13G filing, it indicates a passive investment stake, meaning Armistice Capital is not currently seeking to control or influence the company's management.
• Future changes in Armistice Capital's investment strategy could lead to the sale of its stake, potentially impacting the stock price.

Future Outlook

This filing is primarily a disclosure of ownership and does not contain forward-looking statements or specific future guidance from CalciMedica, Inc.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by investment managers, as seen in this Schedule 13G filing, are common in the biotechnology and pharmaceutical sectors where CalciMedica operates. Such filings often precede or follow periods of company development or strategic shifts.

Comparison to Industry Standards

• The 9.99% ownership threshold reported in this filing is a common level for institutional investors who are significant but not controlling shareholders in publicly traded companies.
• Many biotechnology firms experience substantial institutional ownership, with stakes often ranging from 5% to 20% or more, reflecting the sector's growth potential and associated investment risks.

Stakeholder Impact

• Shareholders may view the acquisition by Armistice Capital as a positive indicator, potentially leading to increased investor interest.
• The passive nature of this investment, as indicated by the 13G filing, suggests no immediate impact on corporate control or strategic direction from Armistice Capital.

Next Steps

• Armistice Capital, LLC will continue to manage the investment in CalciMedica, Inc. according to its investment strategy.
• Further filings may be required if Armistice Capital's ownership stake changes significantly.

Key Dates

Recommendation

The filing indicates a significant passive investment by a professional investment manager, which is a neutral to slightly positive signal. However, without specific financial performance data or strategic updates from CalciMedica itself, a 'hold' recommendation is prudent, awaiting further developments or disclosures from the company.

Keywords

CalciMedica, Armistice Capital, Schedule 13G, Beneficial Ownership, Investment Management, Common Stock, Shareholder